Current stocks of the LCC15-MB cell line, which we originally isolated from a human breast-bone metastasis, were found to be genetically matched to the MDA-MB-435 cell line from the Lombardi Cancer Center (MDA-MB-435-LCC) using comparative genomic hybridisation, DNA microsatellite analysis and chromosomal number. LCC15-MB stocks used for our previously published studies as well as the earliest available LCC15-MB cells also showed identity to MDA-MB-435-LCC cells. The original karyotype reported for LCC15-MB cells was considerably different to that of MDA-MB-435 cells, indicating that the original LCC15-MB cells were lost to contamination by MDA-MB-435-LCC cells. Chromosome number is the simplest test to distinguish original LCC 15-MB cells (n ∼ 75) from MDA-MB-435 (n ∼ 52). Collectively, our results prove that LCC15-MB cells currently available are MDA-MB-435 cells and we suggest their re-designation as MDA-MB-435-LCC15 cells. We also review the known misclassification of breast and prostate cancer cell lines to date and have initiated a register maintained at http://www.svi.edu.au/cell_lines_registry.doc.
Bibliographical noteFunding Information:
This work was primarily supported by the Victorian Breast Cancer Research Consortium, and in part by Breast Cancer Research Foundation grant N003173, US-DOD IDEA grant (BC 021320) and NIH Par 99-128: Insight Awards to Stamp Out Breast Cancer (1 R21 CA87244-01). We thank the Microscopy and Imaging, Tissue Culture, Biostatistics, Research Computing, and Macromolecular Shared Resources of the Lombardi Cancer Center, which are partially supported by PHS grant NIH 1P30-CA-51008 (Cancer Center Support Grant) to Lombardi Cancer Center.
- Breast cancer
- Cell lines
- Chromosomal number
- Microsatellite analysis